Bulletin
Investor Alert

Edwards Lifesciences Corp.

NYS: EW

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Sep 28, 2020, 6:29 p.m.

EW
/zigman2/quotes/205745196/composite

$

77.29

Change

-0.42 -0.54%

Volume

Volume 23,802

Quotes are delayed by 20 min

/zigman2/quotes/205745196/composite

Today's close

$ 77.45

$ 77.71

Change

+0.26 +0.34%

Day low

Day high

$77.49

$78.72

Open

52 week low

52 week high

$51.51

$87.79

Open

Company Description

Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart and Critical Care. The Transcatheter Heart Valves portfolio includes tech...

Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart and Critical Care. The Transcatheter Heart Valves portfolio includes technologies designed to treat heart valve disease using catheter-based approaches as opposed to open surgical techniques. Its portfolio includes technologies designed for nonsurgical replacement of heart valves. The Surgical Structural Heart portfolio includes tissue heart valves and heart valve repair products for the surgical replacement or repair of a patient's heart valve. The Critical Care portfolio products through hemodynamic monitoring system measures a patient's heart function and fluid status in surgical and intensive care settings. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.

Valuation

P/E Current

47.10

P/E Ratio (with extraordinary items)

64.61

P/E Ratio (without extraordinary items)

47.29

Price to Sales Ratio

11.39

Price to Book Ratio

11.76

Price to Cash Flow Ratio

41.97

Enterprise Value to EBITDA

37.01

Enterprise Value to Sales

11.19

Total Debt to Enterprise Value

0.01

Efficiency

Revenue/Employee

312,806.00

Income Per Employee

75,317.00

Receivables Turnover

7.65

Total Asset Turnover

0.74

Liquidity

Current Ratio

3.31

Quick Ratio

2.60

Cash Ratio

1.68

Profitability

Gross Margin

73.43

Operating Margin

27.55

Pretax Margin

26.83

Net Margin

24.08

Return on Assets

17.73

Return on Equity

28.73

Return on Total Capital

27.98

Return on Invested Capital

24.53

Capital Structure

Total Debt to Total Equity

16.36

Total Debt to Total Capital

14.06

Total Debt to Total Assets

10.46

Long-Term Debt to Equity

15.75

Long-Term Debt to Total Capital

13.53

Officers and Executives

Name Age Officer Since Title
Mr. Michael A. Mussallem 66 2000 Chairman & Chief Executive Officer
Mr. Scott B. Ullem 52 2014 Chief Financial Officer & Vice President
Dr. John P. McGrath 59 2006 Vice President-Quality, Regulatory & Clinical
Dr. Todd J. Brinton - 2019 Chief Scientific Officer & VP-Advanced Technology
Mr. Jean-Luc Lemercier - 2017 Corporate Vice President

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
09/15/2020 Scott B. Ullem
CVP, Chief Financial Officer
33,150   Disposition at $83.43 per share. 2,765,704
09/15/2020 Scott B. Ullem
CVP, Chief Financial Officer
33,150   Derivative/Non-derivative trans. at $21.76 per share. 721,344
09/14/2020 Scott B. Ullem
CVP, Chief Financial Officer
26,700   Disposition at $82.21 per share. 2,195,007
09/14/2020 Scott B. Ullem
CVP, Chief Financial Officer
26,700   Derivative/Non-derivative trans. at $13.98 per share. 373,266
09/11/2020 Donald E. Bobo
CVP,Strategy/Corp Development
12,198   Disposition at $82.42 per share. 1,005,359
09/11/2020 Donald E. Bobo
CVP,Strategy/Corp Development
876   Disposition at $82.9 per share. 72,620
09/11/2020 Huimin Wang
CVP, Japan & Intercontinental
11,339   Disposition at $82.43 per share. 934,673
09/11/2020 Huimin Wang
CVP, Japan & Intercontinental
310   Disposition at $82.97 per share. 25,720
09/11/2020 Huimin Wang
CVP, Japan & Intercontinental
81   Disposition at $83 per share. 6,723
09/11/2020 Donald E. Bobo
CVP,Strategy/Corp Development
13,074   Derivative/Non-derivative trans. at $13.98 per share. 182,774
09/11/2020 Huimin Wang
CVP, Japan & Intercontinental
11,649   Derivative/Non-derivative trans. at $13.98 per share. 162,853
09/01/2020 Larry L. Wood
CVP, TAVR
10,698   Disposition at $85.09 per share. 910,292
09/01/2020 Larry L. Wood
CVP, TAVR
10,698   Derivative/Non-derivative trans. at $21.76 per share. 232,788
08/28/2020 Donald E. Bobo
CVP,Strategy/Corp Development
7,200   Disposition at $84.26 per share. 606,672
08/27/2020 Robert W. A. Sellers
VP, Corporate Controller
21,540   Disposition at $82.6 per share. 1,779,204
08/27/2020 Robert W. A. Sellers
VP, Corporate Controller
21,540   Derivative/Non-derivative trans. at $21.76 per share. 468,710
08/19/2020 Michael A. Mussallem
Chairman & CEO; Director
30,000   Gift at $0 per share. 0
08/19/2020 Michael A. Mussallem
Chairman & CEO; Director
98,550   Derivative/Non-derivative trans. at $13.98 per share. 1,377,729
08/19/2020 Michael A. Mussallem
Chairman & CEO; Director
30,000   Gift at $0 per share. 0
08/19/2020 Michael A. Mussallem
Chairman & CEO; Director
59,750   Disposition at $78.97 per share. 4,718,457
08/19/2020 Michael A. Mussallem
Chairman & CEO; Director
8,800   Disposition at $79.57 per share. 700,216
08/14/2020 Donald E. Bobo
CVP,Strategy/Corp Development
13,074   Disposition at $78.75 per share. 1,029,577
08/14/2020 Donald E. Bobo
CVP,Strategy/Corp Development
13,074   Derivative/Non-derivative trans. at $13.98 per share. 182,774
08/13/2020 Donald E. Bobo
CVP,Strategy/Corp Development
5,000   Gift at $0 per share. 0
08/13/2020 Donald E. Bobo
CVP,Strategy/Corp Development
24,324   Gift at $0 per share. 0
08/13/2020 Catherine M. Szyman
CVP, Critical Care
2,249   Disposition at $78.24 per share. 175,961
08/13/2020 Donald E. Bobo
CVP,Strategy/Corp Development
24,324   Gift at $0 per share. 0
08/11/2020 Huimin Wang
CVP, Japan & Intercontinental
11,649   Disposition at $76.04 per share. 885,789
08/11/2020 Huimin Wang
CVP, Japan & Intercontinental
84   Disposition at $76.47 per share. 6,423
08/11/2020 Huimin Wang
CVP, Japan & Intercontinental
11,649   Derivative/Non-derivative trans. at $13.98 per share. 162,853
/news/latest/company/us/ew

MarketWatch News on EW

  1. These 74 stocks in the S&P 500 hit all-time records on Wednesday

    6:55 a.m. Sept. 3, 2020

    - Philip van Doorn

  2. The Dow Is Dropping. Just Don’t Call It a Bad Day.

    2:19 p.m. June 4, 2020

    - Barron's Online

  3. Edwards Lifesciences upgraded to outperform from market perform at SVB Leerink

    6:44 a.m. April 17, 2020

    - Tomi Kilgore

  4. Edwards Lifesciences stock price target cut to $230 from $263 at Raymond James

    7:51 a.m. April 9, 2020

    - Tomi Kilgore

  5. Edwards Lifesciences started at outperform with $280 stock price target at Oppenheimer

    9:52 a.m. Jan. 10, 2020

    - Tomi Kilgore

  6. Edwards Lifesciences stock price target raised to $263 from $255 at Raymond James

    8:40 a.m. Dec. 6, 2019

    - Tomi Kilgore

  7. Edwards Lifesciences stock price target raised to $275 from $250 at Stifel Nicolaus

    8:26 a.m. Dec. 6, 2019

    - Tomi Kilgore

  8. The 3 Best-Performing Health Care Stocks of 2019 So Far

    8:30 a.m. Nov. 28, 2019

    - Barron's Online

  9. Edwards Lifesciences stock price target raised to $250 from $215 at Stifel Nicolaus

    8:17 a.m. Oct. 24, 2019

    - Tomi Kilgore

  10. The Dow Is Up, but This Week Is All About Federal Reserve Signals

    12:36 p.m. Aug. 22, 2019

    - Barron's Online

  11. Edwards Stock Is Soaring, but Analysts Remain Wary

    1:59 p.m. July 24, 2019

    - Barron's Online

  12. Snap Stock Soars, UPS Jumps as Dow Jones Industrial Average Drops

    12:35 p.m. July 24, 2019

    - Barron's Online

  13. Edwards Lifesciences stock price target raised to $225 from $215 at BofA Merrill Lynch

    9:34 a.m. July 24, 2019

    - Tomi Kilgore

  14. Loading more headlines...
/news/nonmarketwatch/company/us/ew

Other News on EW

  1. The Best And Worst Large-Cap Stocks To Buy

    10:26 a.m. Sept. 26, 2020

    - Seeking Alpha

  2. The Best And Worst Large-Cap Stocks To Buy

    10:26 a.m. Sept. 26, 2020

    - Seeking Alpha

  3. Edward Lifesciences: Examining Its Valuation And Fair Value

    10:02 a.m. Sept. 18, 2020

    - Seeking Alpha

  4. Why Stocks Could Be Ready To Rally

    8:58 a.m. Sept. 11, 2020

    - Seeking Alpha

  5. The Sell-Off Accelerates, What To Do Now

    6:47 p.m. Sept. 3, 2020

    - Seeking Alpha

  6. The CVP, TAVR of Edwards Lifesciences is Exercising Options

    8:08 a.m. Sept. 2, 2020

    - SmarterAnalyst

  7. The Best Stocks To Buy On A Sell-Off

    9:21 a.m. Aug. 25, 2020

    - Seeking Alpha

  8. The Most Popular Guru Buys of the 2nd Quarter

    5:23 p.m. Aug. 18, 2020

    - GuruFocus.com

  9. David Rolfe's Top 5 2nd-Quarter Trades

    11:53 a.m. Aug. 18, 2020

    - GuruFocus.com

  10. Why I'm Worrying Over A Market Drop

    4:22 p.m. Aug. 17, 2020

    - Seeking Alpha

  11. Top 5 Latest Buys of Frank Sands' Firm

    4:22 p.m. Aug. 13, 2020

    - GuruFocus.com

  12. TMO vs. EW: Which Stock Is the Better Value Option?

    11:40 a.m. Aug. 6, 2020

    - Zacks.com

  13. Loading more headlines...

At a Glance

Edwards Lifesciences Corp.

One Edwards Way

Irvine, California 92614

Phone

1 9492502500

Industry

Medical Equipment/Supplies

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2020

Revenue

$4.35B

Net Income

$1.05B

2019 Sales Growth

16.8%

Employees

13,900

/news/pressrelease/company/us/ew

Press Releases on EW

  1. Vascular Access Device Market Huge Growth Opportunities and Trends to 2026

    3:55 p.m. Sept. 26, 2020

    - Market Insight Reports

  2. Loading more headlines...
Link to MarketWatch's Slice.